The Centers for Women's Health in Stamford CT Pioneers Breast Cancer Risk Assessment

The Centers for Women's Health in Stamford CT Pioneers Breast Cancer Risk

Local Physician One of the First in Nation to Use New Breast Cancer Predictive
Risk Test

STAMFORD, Conn., March 18, 2013 (GLOBE NEWSWIRE) -- Dr. Joel Evans, Founder
and Director of The Center for Women's Health, is one of the first physicians
in the nation to make the BREVAGen™ predictive risk test available to his
patients. Clinically validated, BREVAGen is the latest advance in assessing a
woman's unique risk of developing non-familial or sporadic breast cancer.

"At The Center for Women's Health, we believe that optimal healthcare combines
the best of modern medicine with the wisdom of traditional healing," said Dr.
Joel Evans, Founder and Director of The Center for Women's Health. "BREVAGen
enables us to accurately assess a woman's overall risk of developing breast
cancer so we can create appropriate plans to minimize her risk, including more
informed decisions about hormone replacement therapies, breast monitoring and
surveillance schedules, and lifestyle choices."

BREVAGen is a clinically validated predictive risk test that more accurately
identifies a woman's unique risk of developing sporadic, estrogen-positive
breast cancer. BREVAGen examines a woman's clinical risk factors, such as
their lifetime exposure to estrogen, combined with scientifically validated
markers to determine each patient's personalized five-year and lifetime risk
of developing breast cancer.1 BREVAGen is supplied by Phenogen Sciences, a
subsidiary of Genetic Technologies Limited (Nasdaq:GENE). For more information
about The Center for Women's Health use of BREVAGen, contact Mary Kate DiSalvo
at (203) 321-0200.

How BREVAGen Works


The BREVAGen predictive risk test is administered in a physician's office
using a simple, non-invasive "oral-swab". Following analysis in a
CLIA-certified laboratory, physicians receive a comprehensive genetic risk
prediction report to review with the patient. The patient's risk of breast
cancer is calculated by combining their relative risk score from seven genetic
markers, called SNPs (single nucleotide polymorphisms), with factors that
comprise the patient's clinical and reproductive history including current
age, age at menarche, age at live first birth and race/ethnicity.

The BREVAGen test provides five-year and lifetime predictive risk assessments
to more accurately evaluate the patient's risk for developing sporadic breast
cancer, regardless of family history or previous indeterminate test results.

Clinically Validated

BREVAGen was proven superior in determining breast cancer risk compared to
Gail score alone.1 Utilizing data from the U.S. Women's Health Initiative
(WHI) Clinical Trial, 3,300 women underwent breast cancer assessment utilizing
the BREVAGen test. Of those 3,300 women, 1,664 were diagnosed with breast
cancer and 1,636 were in the breast cancer-free control group. BREVAGen test
results support current American Cancer Society (ACS) [],
American Society of Clinical Oncology (ASCO) [] and The National
Comprehensive Care Network (NCCN) [] guidelines for prevention and
early detection of breast cancer.2, 3

About The Center for Women's Health

The Center for Women's Health is a state-of-the-art women's health center,
combining the best of modern medicine with the wisdom of traditional healing.
Patients at the Center are offered the most up to date leading edge medical
evaluation and treatment as well as scientifically studied, natural holistic
options individually designed to improve their health and prevent disease. For
additional information about The Center for Women's Health, please visit

About Phenogen Sciences

Phenogen Sciences, the U.S. subsidiary of Australia-based Genetic Technologies
Limited, is a pioneer in personalized healthcare. Phenogen offers novel
predictive testing and assessment tools that help physicians proactively
manage women's health risks.

Phenogen's lead product, BREVAGen, is a clinically validated test that
combines a woman's clinical history of estrogen exposure with her genetic
predisposition to its effects - more accurately categorizing her personal risk
for developing breast cancer. For more information, visit

About Genetic Technologies Limited

Genetic Technologies is an established diagnostics company with more than 20
years of experience in commercializing genetic testing, non-coding DNA and
product patenting. The company has operations in Australia and the U.S. and is
dual-listed on the ASX (GTG.AX) and NASDAQ (GENE). Genetic Technologies is
focused on the commercialization of its patent portfolio through an active
out-licensing program and the global expansion of its oncology and cancer
management diagnostics assets. For more information, please visit

1 Mealiffe M, Stokowski RP, Rhees, BK, et al. J Nat Cancer Inst.
2 Saslow D, Boetes C, Burke W, et al. CA Cancer J Clin. 2007;57(2):75-89.
3 Visvanathan K, Chlebowski RT, Hurley P, et al. J Clin Oncol.
4 Breast Cancer Overview. American Cancer Society. Accessed 3/14/12 at
5 DeSantis C, Siegel R, Bandi P, Jemal A. CA: A Cancer Journal For Clinicians.
2011;61: 409-418

Additional Information

About Breast Cancer

• Approximately one in eight women will get breast cancer4
• 70% to 80% of those who get breast cancer do not have familial risk
• Risk of invasive vs. non-invasive breast cancer is approximately four times
greater in women age 40-645
• Approximately 75% of all breast cancer is estrogen-positive and, if detected
early, can be effectively treated with five-year survival rates of over 95%

Breast Cancer Demographics

According to the American Cancer Society, breast cancer is the most common
cancer among women in the United States, other than skin cancer. It is the
second leading cause of death in women, after lung cancer.4 According to the
2010 breast cancer demographics there are:

• Approximately 207,000 new cases diagnosed each year4
• Of the 207,000 new cases, about 54,000 are non-invasive forms of breast
cancer that have been diagnosed early4
• Approximately 40,000 deaths related to breast cancer in women, annually4

BREVAGen reclassified 64% of above average Gail risk subjects1 (see attached
chart for more information)

BREVAGen reclassified 64% of Gail scores above average risk subjects as either
high or low risk for development of hormone-dependent breast cancer.
Furthermore, the BREVAGen test reclassified the breast cancer risk for 33% of
the total 3,300 trial subjects.1

About BREVAGen™

The first product in Phenogen Science's portfolio, BREVAGen™ is a predictive
risk test for sporadic, hormone-dependent breast cancer. The BREVAGen test
combines a woman's clinical history of estrogen exposure with the presence of
identified genetic markers to determine her five-year and lifetime risk for
developing breast cancer. For women whose clinical profile indicates prolonged
estrogen exposure, BREVAGen helps to provide a more accurate risk assessment
for estrogen-positive breast cancer. The test results assist physicians in
developing a personalized care path toward managing each woman's risk of
developing breast cancer with greater precision than ever before.

• Non-invasive, easy-to-use predictive risk assessment test
• The first genetic risk prediction test to have been validated in a
large-scale, peer-reviewed, case-controlled study1
• Recent studies demonstrate that 64% of women who have above average risk of
prolonged estrogen exposure were either reclassified above the guidelines for
high risk management or below the general population risk when compared to
clinical risk factors alone1
• Supports existing industry guidelines for the prevention of
estrogen-positive breast cancer2,3

Click here for BREVAGen B-roll/video:

• Video One: &feature=plcp
• Video Two: &feature=plcp

A photo accompanying this release is available at:

CONTACT: Andrea Preston
         Kovak-Likly Communications
         (203) 762-8833
Press spacebar to pause and continue. Press esc to stop.